GlobeNewswire: Gemphire Therapeutics Inc. Contains the last 10 of 74 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:35:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/12/30/1965077/0/en/Gemphire-Therapeutics-Announces-Expected-Closing-Date-of-Merger-with-NeuroBo-Pharmaceuticals.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals2019-12-30T16:08:12Z<![CDATA[ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions.]]>https://www.globenewswire.com/news-release/2019/12/06/1957305/0/en/Gemphire-Therapeutics-Announces-Stockholder-Approval-of-Proposals-Required-for-Merger-with-NeuroBo-Pharmaceuticals.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals2019-12-06T13:42:58Z<![CDATA[ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all of the merger-related proposals, including: (i) the issuance of Gemphire common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated July 24, 2019, by and among Gemphire, GR Merger Sub Inc. and NeuroBo Pharmaceuticals, Inc. and the change of control of Gemphire resulting from the merger, (ii) a reverse stock split of Gemphire common stock, at a ratio of one new share for every 15 to 25 shares outstanding and (iii) changing the name of Gemphire from “Gemphire Therapeutics Inc.” to “NeuroBo Pharmaceuticals, Inc.”]]>https://www.globenewswire.com/news-release/2019/08/09/1899910/0/en/Gemphire-Therapeutics-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update2019-08-09T12:00:00Z<![CDATA[LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH), today announced financial results for the quarter and six months ended June 30, 2019, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2019/07/26/1892176/0/en/Gemphire-Therapeutics-and-NeuroBo-Pharmaceuticals-Announce-Merger-Agreement-to-Advance-a-Neurodegenerative-Disease-Company.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company2019-07-26T10:01:27Z<![CDATA[Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline]]>https://www.globenewswire.com/news-release/2019/07/26/1892176/0/ko/Gemphire-Therapeutics%EC%99%80-NeuroBo-Pharmaceuticals-%ED%87%B4%ED%96%89%EC%84%B1-%EC%A7%88%ED%99%98-%EC%B9%98%EB%A3%8C%EC%A0%9C-%EA%B0%9C%EB%B0%9C-%EC%9C%84%ED%95%9C-%ED%86%B5%ED%95%A9-%EB%B2%95%EC%9D%B8-%EC%84%A4%EB%A6%BD-%EC%9C%84%ED%95%B4-%ED%95%A9%EB%B3%91-%ED%95%A9%EC%9D%98.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics와 NeuroBo Pharmaceuticals, 퇴행성 질환 치료제 개발 위한 통합 법인 설립 위해 합병 합의2019-07-26T10:01:27Z<![CDATA[Nasdaq 상장사이자 NeuroBo의 임상단계 파이프라인 발전시킬 바이오 기술기업 탄생]]>https://www.globenewswire.com/news-release/2019/07/24/1887477/0/en/Gemphire-Therapeutics-and-NeuroBo-Pharmaceuticals-Announce-Merger-Agreement-to-Advance-a-Neurodegenerative-Disease-Company.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company2019-07-24T20:01:00Z<![CDATA[Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline]]>https://www.globenewswire.com/news-release/2019/06/26/1874406/0/en/Gemphire-Announces-Top-Line-Data-from-Familial-Partial-Lipodystrophy-FPLD-Phase-2a-Proof-of-Concept-NAFLD-NASH-Clinical-Trial.html?f=22&fvtc=4&fvtv=29297Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial2019-06-26T12:00:00Z<![CDATA[Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients]]>https://www.globenewswire.com/news-release/2019/03/15/1755229/0/en/Gemphire-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2018-Financial-Results.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results2019-03-15T12:00:00Z<![CDATA[LIVONIA, Mich., March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH), today announced its financial results for the quarter and fiscal year ended December 31, 2018, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2018/12/03/1660762/0/en/Gemphire-Therapeutics-Announces-Review-of-Strategic-Alternatives-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update2018-12-03T13:00:00Z<![CDATA[LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that its Board of Directors is conducting a review of a range of strategic alternatives focused on maximizing stockholder value. The Company has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for this process.]]>https://www.globenewswire.com/news-release/2018/11/08/1648469/0/en/Gemphire-Therapeutics-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=29297Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update2018-11-08T21:01:00Z<![CDATA[LIVONIA, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced financial results for the quarter and nine months ended September 30, 2018, and provided a corporate update.]]>